Federated Hermes
PTGX icon

Federated Hermes’s Protagonist Therapeutics PTGX Stock Holding History

Federated Hermes’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,001
Closed -$106K – 2149
2026
Q1 		$106K Buy
+1,001
New +$88.6K ﹤0.01% 1581
2025
Q1 		– Sell
-7
Closed -$270 – 2176
2024
Q4 		$270 Buy
+7
New +$305 ﹤0.01% 2048
2023
Q4 		– Sell
-60,234
Closed -$1M – 2175
2023
Q3 		$1M Buy
60,234
+30,507
+103% +$592K ﹤0.01% 1110
2023
Q2 		$821K Buy
29,727
+74
+0.2% +$1.85K ﹤0.01% 1200
2023
Q1 		$682K Sell
29,653
-17,155
-37% -$288K ﹤0.01% 1305
2022
Q4 		$511K Buy
+46,808
New +$395K ﹤0.01% 1363
2022
Q3 		– Sell
-28
Closed -$1K – 2223
2022
Q2 		$1K Buy
+28
New +$339 ﹤0.01% 2071
2021
Q4 		– Sell
-131,282
Closed -$2.33M – 2287
2021
Q3 		$2.33M Buy
131,282
+69,267
+112% +$2.95M ﹤0.01% 1002
2021
Q2 		$2.78M Buy
+62,015
New +$2.05M 0.01% 995
2021
Q1 		– Sell
-42,992
Closed -$867K – 2329
2020
Q4 		$867K Buy
42,992
+42,887
+40,845% +$923K ﹤0.01% 1376
2020
Q3 		$2K Buy
+105
New +$1.97K ﹤0.01% 2104
2019
Q3 		– Sell
-304
Closed -$4K – 2276
2019
Q2 		$4K Buy
304
+130
+75% +$1.44K ﹤0.01% 2020
2019
Q1 		$2K Buy
+174
New +$1.54K ﹤0.01% 2071
2018
Q3 		– Sell
-12,682
Closed -$85K – 2314
2018
Q2 		$85K Sell
12,682
-51,239
-80% -$393K ﹤0.01% 1626
2018
Q1 		$549K Buy
63,921
+46,496
+267% +$876K ﹤0.01% 1369
2017
Q4 		$362K Buy
+17,425
New +$309K ﹤0.01% 1436

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Federated Hermes's PTGX Position: Q2 2026 in Review

Federated Hermes sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 1,001 shares — an estimated $106K sold.

Federated Hermes first reported a position in PTGX in Q4 2017 and held it in 16 quarters. The position peaked at $2.78M in Q2 2021. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Federated Hermes reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Federated Hermes sold 1,001 Protagonist Therapeutics shares in Q2 2026, an estimated $106K.
  • Federated Hermes first reported a position in Protagonist Therapeutics in Q4 2017 and held it in 16 quarters.
  • Federated Hermes's Protagonist Therapeutics position peaked at $2.78M in Q2 2021.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.